HK Stock Market Move | CANSINOBIO (06185) rises more than 3%, 2024 revenue increased by 131%-142% year-on-year.

CANSINOBIO (06185) rose more than 3%, as of the time of writing, it rose by 2.13%, to 28.8 Hong Kong dollars, with a turnover of 107.064 million Hong Kong dollars. In terms of news, recently, CANSINOBIO issued a profit warning, expecting a net loss between 335 million to 385 million RMB for the fiscal year 2024, compared to a profit of 1.483 billion RMB in the previous year. This was mainly due to the rapid growth in operating income, driving an improvement in operating results. For the year, operating income is expected to be between 825 million and 865 million RMB, a year-on-year increase of 131% to 142%. During the reporting period, the focus of this group's work was mainly on advancing the commercialization process of meningococcal B vaccine and the research and development of non-COVID vaccines. In the commercialization of vaccines, the group continued to establish sales channels. The group's ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) (trade name: Manhixinci) is currently in a leading competitive position, with a continuously increasing market share, and the group's operations have been largely unaffected by global public health events. Therefore, the group's operating income has grown rapidly compared to the same period last year, driving an improvement in the group's operating results.